James Moy to Adolescent
This is a "connection" page, showing publications James Moy has written about Adolescent.
Connection Strength
0.337
-
Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study. Eur J Pharm Sci. 2018 Jun 15; 118:80-86.
Score: 0.095
-
Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga?) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study. J Clin Immunol. 2017 Aug; 37(6):603-612.
Score: 0.091
-
Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma. N Engl J Med. 2019 09 26; 381(13):1227-1239.
Score: 0.027
-
Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level. N Engl J Med. 2019 05 23; 380(21):2009-2019.
Score: 0.026
-
Serum vitamin A, zinc and visual function in children with moderate to severe persistent asthma. J Asthma. 2019 Nov; 56(11):1198-1203.
Score: 0.025
-
Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases. Immunotherapy. 2018 10; 10(14):1193-1202.
Score: 0.025
-
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex? 10% Versus Gammaplex? 5% in Subjects with Primary Immunodeficiency. J Clin Immunol. 2017 Apr; 37(3):301-310.
Score: 0.022
-
Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency. J Clin Immunol. 2010 Mar; 30(2):321-9.
Score: 0.013
-
A community-based study of tobacco smoke exposure among inner-city children with asthma in Chicago. J Allergy Clin Immunol. 2008 Oct; 122(4):754-759.e1.
Score: 0.012